hemophilia articles & resources on Made-in-China.com

Researchers Have Color-Coded Cells in Female Mice to Display Silenced

Jan 13, 2014

Producing brightly speckled red and green snapshots of many different tissues, Johns Hopkins researchers have color-coded cells in female mice to display which of their two X chromosomes has been made inactive, or “silenced.” ...

Tags: X chromosomes, Johns Hopkins, color-coded cells, genetic diversity

Ten Transgenic Piglets Have Been Born This Year in Guangdong Province

Dec 25, 2013

Along with red, green is the color of this holiday season. And bright green is showing up in more than just decorations. ?In Guangdong Province in Southern China, ten transgenic piglets have been born this year, six of them since August, ...

Tags: Consumer Electronics, Electronics

Baxter Today Announced Completion of CE Marking in Europe for The VIVIA HD System

Dec 23, 2013

Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High ...

Tags: CE, health, medicine

Baxter International Submitted a BLA to FDA for Approval of 'OBI-1'

Dec 12, 2013

Baxter International has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of a recombinant antihemophilic porcine sequence factor VIII called 'OBI-1' for the treatment of patients ...

Tags: Baxter, Medicine

Baxter International Has Filed an Application to The US Food and Drug Administration

Dec 11, 2013

Baxter International has filed an application to the US Food and Drug Administration (FDA) for a pediatric indication for Rixubis [Coagulation Factor IX (Recombinant)] to treat hemophilia B. The submission was based on a Phase II/III ...

Tags: Baxter, Medicine

FDA Extended Its Review of a Marketing Application for Fusion Protein Alprolix

Dec 5, 2013

Biogen Idec announced that the US Food and Drug Administration (FDA) has extended its review of a marketing application for the long-lasting recombinant factor IX Fc fusion protein Alprolix for haemophilia B by three months. The company ...

Tags: Health, Medicine

Baxter Has Submitted a Marketing Authorization Application to The EMA

Nov 4, 2013

Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of Rixubis, recombinant factor IX for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. ...

Tags: Baxter, European Medicines Agency

A Gene Therapy Company Focused on Developing Novel Treatments for Rare Diseases

Nov 4, 2013

Fidelity Biosciences, a subsidiary of Fidelity Investments, and US-based Regenx Biosciences have announced the formation of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension ...

Tags: Biosciences, Health, Medicine

Inherited Diseases Are The Passing of Bad Characteristics From Generation to Generation

Sep 10, 2013

A disease, by definition, is a disorder of structure or function in an organism that produces specific symptoms or signs to indicate its presence. Inheritance, in terms of biology, is the passing of characteristics, good or bad, from ...

Tags: Inherited Blood Diseases, Health, Medicine

Alnylam Pharmaceuticals Has Obtained Additional Orphan Drug Designation

Aug 22, 2013

RNAi therapeutics company Alnylam Pharmaceuticals has obtained additional orphan drug designation from US FDA for a RNAi therapeutic, ALN-AT3, to treat hemophilia A. With the additional approval, orphan drug designation for GalNAc ...

Tags: Alnylam, Orphan Drug

Biogen Idec Is Seeking Marketing Approval From The US FDA

Mar 14, 2013

Biogen Idec is seeking marketing approval from the US Food and Drug Administration (FDA) for recombinant factor VIII Fc fusion protein (rFVIIIFc) therapy to treat hemophilia A. The company has submitted a biologics license application ...

Tags: Biogen Idec, FDA, hemophilia A

FDA Has Accepted Biogen Idec's Biologics License Application for The Marketing Approval

Mar 6, 2013

The US Food and Drug Administration (FDA) has accepted Biogen Idec's biologics license application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. Using the company's ...

Tags: FDA, Idec BLA, hemophilia B

Baxter Has Submitted a BLA to The US FDA

Feb 28, 2013

Baxter has submitted a biologics license application (BLA) supplement to the US Food and Drug Administration (FDA) for the approval of its prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, ...

Tags: Baxter, Feiba NF Drug, Medicine

Novo Nordisk Announced The Introduction of HemaGo

Jan 14, 2013

Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact ...

Tags: Novo Nordisk, HemaGo, mobile application, hemophilia, treatment

The Drug Candidate Is Being Studied to Treat Acquired Hemophilia a Individuals

Dec 14, 2012

Ipsen and Inspiration Biopharmaceuticals have announced FDA Fast Track status to an intravenous recombinant porcine factor VIII, OBI-1, for acquired hemophilia A therapy. The drug candidate is being studied to treat acquired hemophilia A ...

Tags: FDA, fast track status, drug candidate

hemophilia

Related Products